Summary
This in silico study computationally optimised isatin-linked chalcone compounds for binding to InhA, a key tuberculosis target protein. Four lead compounds (6, 7, 8, 9) showed docking scores of −10.2 to −10.5, exceeding the standard anti-tubercular drug isoniazid (−10.3 in this domain). The authors propose these compounds warrant further in vitro and in vivo evaluation as potential tuberculosis therapeutics, though no experimental validation is presented.
UK applicability
This computational screening study is relevant to tuberculosis drug discovery globally, including the United Kingdom context of antibiotic resistance. However, translation to clinical benefit requires in vitro and in vivo validation before any UK therapeutic development or policy implications can be assessed.
Key measures
Docking scores (binding affinity predictions) for chalcone isatin analogues versus isoniazid against NADH-dependent enoyl-ACP reductase (InhA protein 4QXM)
Outcomes reported
The study evaluated docking scores of chalcone isatin compounds against the tuberculosis target protein InhA (4QXM), comparing binding affinity to the standard anti-tubercular drug isoniazid. Compounds 6, 7, 8, and 9 demonstrated superior docking scores (−10.2 to −10.5) compared to isoniazid (−10.3 in this domain, −6.1 in standard assays), indicating stronger predicted protein binding affinity.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.